Stockholm, March 11, 2016 – Trimb Healthcare AB (“Trimb”) has acquired CCS Healthcare AB’s (“CCS”) OTC pharmaceutical products in the Nordics. The products, which include Cortimyk (treatment of foot fungus), Hydrokortison CCS (treatment of mild eczema) and Propyless (treatment of dry skin) among others, are well established in their markets and generate total revenues of approximately €10 million annually.
“Trimb already enjoys strong organic sales growth in the Nordics and in other northern European markets. The acquisition of the CCS portfolio strengthens our position in dermatology and expands our pipeline for the future,” said Magnus Kamryd, CEO of Trimb.
The purchase price, which was not disclosed, was fully underwritten by Trimb’s lead investor, Avista Capital Partners, a leading private equity firm.
For more information, please contact:
Anders Larnholt, VP M&A Trimb
Email: [email protected]
Phone: +46 76 677 64 95
Trimb Healthcare AB
Trimb is a rapidly growing OTC and consumer healthcare company based in Stockholm, Sweden. Our experience and competencies span across all regulatory classes and most therapy fields relevant to consumer healthcare. Trimb’s products are sold in more than 50 countries and the company has its own go-to-market organization in Northern Europe.